Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CombiflexOmega peri
- Development stage
- Phase 3
- Lead developer
- B. Braun
- Administration
- Intravenous
01
Overview
CombiflexOmega peri appears to be a parenteral nutrition solution intended for peripheral infusion. It likely contains a combination of amino acids, lipids (including omega fatty acids), glucose, and electrolytes for patients with moderately increased, basal or low nutritional requirements when oral or enteral nutrition is impossible, insufficient or contraindicated. The product is designed for intravenous administration through peripheral veins.
- Brand names
- CombiflexOmega peri
- Other names
- Combiflex Omega Peripheral
Beyond the preview
Go deeper on CombiflexOmega peri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CombiflexOmega peri.